Global Ciclopirox Olamine 麻豆原创 Research Report 2023

Publication ID:

PB504244234

Publication Date:

May 10, 2023

Pages:

101

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Highlights
The global Ciclopirox Olamine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Ciclopirox Olamine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Ciclopirox Olamine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Ciclopirox Olamine in Ringworm Of The Body is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Ciclopirox Olamine include Bayer, Apotex Corporation, Fougera (Sandoz), Medimetriks Pharmaceuticals, Taro Pharmaceuticals, Preferred Pharmaceuticals, Ingenus Pharmaceuticals, Alvogen (CVC Capital Partners and Temasek ) and Acella Pharmaceuticals, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ciclopirox Olamine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ciclopirox Olamine.
The Ciclopirox Olamine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Ciclopirox Olamine market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ciclopirox Olamine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bayer
Apotex Corporation
Fougera (Sandoz)
Medimetriks Pharmaceuticals
Taro Pharmaceuticals
Preferred Pharmaceuticals
Ingenus Pharmaceuticals
Alvogen (CVC Capital Partners and Temasek )
Acella Pharmaceuticals
Dr Marc's Manufacturing
Paddock Laboratories (Perrigo)
Sincerus
Glades Pharmaceuticals (GSK)
Sterimax
Guangzhou Kanghe Pharmaceutical
Tianjin Lisheng Pharmaceutical
Zhejiang Xianju Pharmaceutical
Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding)
Segment by Type
Cream Preparation
Temperture
Vaginal Suppository
Segment by Application
Ringworm Of The Body
Athlete'S Foot
Tinea
Tinea Versicolor
Candida Albicans
Gynecological Anti-Infection Preparation
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ciclopirox Olamine companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Ciclopirox Olamine 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cream Preparation
1.2.3 Temperture
1.2.4 Vaginal Suppository
1.3 麻豆原创 by Application
1.3.1 Global Ciclopirox Olamine 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Ringworm Of The Body
1.3.3 Athlete'S Foot
1.3.4 Tinea
1.3.5 Tinea Versicolor
1.3.6 Candida Albicans
1.3.7 Gynecological Anti-Infection Preparation
1.3.8 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ciclopirox Olamine 麻豆原创 Perspective (2018-2029)
2.2 Ciclopirox Olamine Growth Trends by Region
2.2.1 Global Ciclopirox Olamine 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Ciclopirox Olamine Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Ciclopirox Olamine Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Ciclopirox Olamine 麻豆原创 Dynamics
2.3.1 Ciclopirox Olamine Industry Trends
2.3.2 Ciclopirox Olamine 麻豆原创 Drivers
2.3.3 Ciclopirox Olamine 麻豆原创 Challenges
2.3.4 Ciclopirox Olamine 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ciclopirox Olamine Players by Revenue
3.1.1 Global Top Ciclopirox Olamine Players by Revenue (2018-2023)
3.1.2 Global Ciclopirox Olamine Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Ciclopirox Olamine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ciclopirox Olamine Revenue
3.4 Global Ciclopirox Olamine 麻豆原创 Concentration Ratio
3.4.1 Global Ciclopirox Olamine 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ciclopirox Olamine Revenue in 2022
3.5 Ciclopirox Olamine Key Players Head office and Area Served
3.6 Key Players Ciclopirox Olamine Product Solution and Service
3.7 Date of Enter into Ciclopirox Olamine 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Ciclopirox Olamine Breakdown Data by Type
4.1 Global Ciclopirox Olamine Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Ciclopirox Olamine Forecasted 麻豆原创 Size by Type (2024-2029)
5 Ciclopirox Olamine Breakdown Data by Application
5.1 Global Ciclopirox Olamine Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Ciclopirox Olamine Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Ciclopirox Olamine 麻豆原创 Size (2018-2029)
6.2 North America Ciclopirox Olamine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Ciclopirox Olamine 麻豆原创 Size by Country (2018-2023)
6.4 North America Ciclopirox Olamine 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ciclopirox Olamine 麻豆原创 Size (2018-2029)
7.2 Europe Ciclopirox Olamine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Ciclopirox Olamine 麻豆原创 Size by Country (2018-2023)
7.4 Europe Ciclopirox Olamine 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ciclopirox Olamine 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Ciclopirox Olamine 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Ciclopirox Olamine 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Ciclopirox Olamine 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ciclopirox Olamine 麻豆原创 Size (2018-2029)
9.2 Latin America Ciclopirox Olamine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Ciclopirox Olamine 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Ciclopirox Olamine 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ciclopirox Olamine 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Ciclopirox Olamine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Ciclopirox Olamine 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Ciclopirox Olamine 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Ciclopirox Olamine Introduction
11.1.4 Bayer Revenue in Ciclopirox Olamine Business (2018-2023)
11.1.5 Bayer Recent Development
11.2 Apotex Corporation
11.2.1 Apotex Corporation Company Detail
11.2.2 Apotex Corporation Business Overview
11.2.3 Apotex Corporation Ciclopirox Olamine Introduction
11.2.4 Apotex Corporation Revenue in Ciclopirox Olamine Business (2018-2023)
11.2.5 Apotex Corporation Recent Development
11.3 Fougera (Sandoz)
11.3.1 Fougera (Sandoz) Company Detail
11.3.2 Fougera (Sandoz) Business Overview
11.3.3 Fougera (Sandoz) Ciclopirox Olamine Introduction
11.3.4 Fougera (Sandoz) Revenue in Ciclopirox Olamine Business (2018-2023)
11.3.5 Fougera (Sandoz) Recent Development
11.4 Medimetriks Pharmaceuticals
11.4.1 Medimetriks Pharmaceuticals Company Detail
11.4.2 Medimetriks Pharmaceuticals Business Overview
11.4.3 Medimetriks Pharmaceuticals Ciclopirox Olamine Introduction
11.4.4 Medimetriks Pharmaceuticals Revenue in Ciclopirox Olamine Business (2018-2023)
11.4.5 Medimetriks Pharmaceuticals Recent Development
11.5 Taro Pharmaceuticals
11.5.1 Taro Pharmaceuticals Company Detail
11.5.2 Taro Pharmaceuticals Business Overview
11.5.3 Taro Pharmaceuticals Ciclopirox Olamine Introduction
11.5.4 Taro Pharmaceuticals Revenue in Ciclopirox Olamine Business (2018-2023)
11.5.5 Taro Pharmaceuticals Recent Development
11.6 Preferred Pharmaceuticals
11.6.1 Preferred Pharmaceuticals Company Detail
11.6.2 Preferred Pharmaceuticals Business Overview
11.6.3 Preferred Pharmaceuticals Ciclopirox Olamine Introduction
11.6.4 Preferred Pharmaceuticals Revenue in Ciclopirox Olamine Business (2018-2023)
11.6.5 Preferred Pharmaceuticals Recent Development
11.7 Ingenus Pharmaceuticals
11.7.1 Ingenus Pharmaceuticals Company Detail
11.7.2 Ingenus Pharmaceuticals Business Overview
11.7.3 Ingenus Pharmaceuticals Ciclopirox Olamine Introduction
11.7.4 Ingenus Pharmaceuticals Revenue in Ciclopirox Olamine Business (2018-2023)
11.7.5 Ingenus Pharmaceuticals Recent Development
11.8 Alvogen (CVC Capital Partners and Temasek )
11.8.1 Alvogen (CVC Capital Partners and Temasek ) Company Detail
11.8.2 Alvogen (CVC Capital Partners and Temasek ) Business Overview
11.8.3 Alvogen (CVC Capital Partners and Temasek ) Ciclopirox Olamine Introduction
11.8.4 Alvogen (CVC Capital Partners and Temasek ) Revenue in Ciclopirox Olamine Business (2018-2023)
11.8.5 Alvogen (CVC Capital Partners and Temasek ) Recent Development
11.9 Acella Pharmaceuticals
11.9.1 Acella Pharmaceuticals Company Detail
11.9.2 Acella Pharmaceuticals Business Overview
11.9.3 Acella Pharmaceuticals Ciclopirox Olamine Introduction
11.9.4 Acella Pharmaceuticals Revenue in Ciclopirox Olamine Business (2018-2023)
11.9.5 Acella Pharmaceuticals Recent Development
11.10 Dr Marc's Manufacturing
11.10.1 Dr Marc's Manufacturing Company Detail
11.10.2 Dr Marc's Manufacturing Business Overview
11.10.3 Dr Marc's Manufacturing Ciclopirox Olamine Introduction
11.10.4 Dr Marc's Manufacturing Revenue in Ciclopirox Olamine Business (2018-2023)
11.10.5 Dr Marc's Manufacturing Recent Development
11.11 Paddock Laboratories (Perrigo)
11.11.1 Paddock Laboratories (Perrigo) Company Detail
11.11.2 Paddock Laboratories (Perrigo) Business Overview
11.11.3 Paddock Laboratories (Perrigo) Ciclopirox Olamine Introduction
11.11.4 Paddock Laboratories (Perrigo) Revenue in Ciclopirox Olamine Business (2018-2023)
11.11.5 Paddock Laboratories (Perrigo) Recent Development
11.12 Sincerus
11.12.1 Sincerus Company Detail
11.12.2 Sincerus Business Overview
11.12.3 Sincerus Ciclopirox Olamine Introduction
11.12.4 Sincerus Revenue in Ciclopirox Olamine Business (2018-2023)
11.12.5 Sincerus Recent Development
11.13 Glades Pharmaceuticals (GSK)
11.13.1 Glades Pharmaceuticals (GSK) Company Detail
11.13.2 Glades Pharmaceuticals (GSK) Business Overview
11.13.3 Glades Pharmaceuticals (GSK) Ciclopirox Olamine Introduction
11.13.4 Glades Pharmaceuticals (GSK) Revenue in Ciclopirox Olamine Business (2018-2023)
11.13.5 Glades Pharmaceuticals (GSK) Recent Development
11.14 Sterimax
11.14.1 Sterimax Company Detail
11.14.2 Sterimax Business Overview
11.14.3 Sterimax Ciclopirox Olamine Introduction
11.14.4 Sterimax Revenue in Ciclopirox Olamine Business (2018-2023)
11.14.5 Sterimax Recent Development
11.15 Guangzhou Kanghe Pharmaceutical
11.15.1 Guangzhou Kanghe Pharmaceutical Company Detail
11.15.2 Guangzhou Kanghe Pharmaceutical Business Overview
11.15.3 Guangzhou Kanghe Pharmaceutical Ciclopirox Olamine Introduction
11.15.4 Guangzhou Kanghe Pharmaceutical Revenue in Ciclopirox Olamine Business (2018-2023)
11.15.5 Guangzhou Kanghe Pharmaceutical Recent Development
11.16 Tianjin Lisheng Pharmaceutical
11.16.1 Tianjin Lisheng Pharmaceutical Company Detail
11.16.2 Tianjin Lisheng Pharmaceutical Business Overview
11.16.3 Tianjin Lisheng Pharmaceutical Ciclopirox Olamine Introduction
11.16.4 Tianjin Lisheng Pharmaceutical Revenue in Ciclopirox Olamine Business (2018-2023)
11.16.5 Tianjin Lisheng Pharmaceutical Recent Development
11.17 Zhejiang Xianju Pharmaceutical
11.17.1 Zhejiang Xianju Pharmaceutical Company Detail
11.17.2 Zhejiang Xianju Pharmaceutical Business Overview
11.17.3 Zhejiang Xianju Pharmaceutical Ciclopirox Olamine Introduction
11.17.4 Zhejiang Xianju Pharmaceutical Revenue in Ciclopirox Olamine Business (2018-2023)
11.17.5 Zhejiang Xianju Pharmaceutical Recent Development
11.18 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding)
11.18.1 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Company Detail
11.18.2 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Business Overview
11.18.3 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Ciclopirox Olamine Introduction
11.18.4 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Revenue in Ciclopirox Olamine Business (2018-2023)
11.18.5 Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Bayer
Apotex Corporation
Fougera (Sandoz)
Medimetriks Pharmaceuticals
Taro Pharmaceuticals
Preferred Pharmaceuticals
Ingenus Pharmaceuticals
Alvogen (CVC Capital Partners and Temasek )
Acella Pharmaceuticals
Dr Marc's Manufacturing
Paddock Laboratories (Perrigo)
Sincerus
Glades Pharmaceuticals (GSK)
Sterimax
Guangzhou Kanghe Pharmaceutical
Tianjin Lisheng Pharmaceutical
Zhejiang Xianju Pharmaceutical
Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.